<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943369</url>
  </required_header>
  <id_info>
    <org_study_id>IIS13616</org_study_id>
    <nct_id>NCT02943369</nct_id>
  </id_info>
  <brief_title>Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI</brief_title>
  <official_title>Cangrelor Administration Following Ticagrelor Loading vs Ticagrelor Loading Alone in ST Segment Elevation Myocardial Infarction Patients: A Randomized, Pharmacodynamic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Attikon Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AHEPA University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Alexandroupolis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Attikon Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Platelets and thrombus formation play a key role in the pathogenesis of acute coronary artery&#xD;
      occlusion and subsequent myocardial infarction. Apart from mechanically opening the occluded&#xD;
      artery with angioplasty, adjunctive antiplatelet treatment is of utmost importance. However,&#xD;
      orally administered antiplatelet agents exhibit a delay in their onset of action in the&#xD;
      setting of acute myocardial infarction and angioplasty is mostly performed without adequate&#xD;
      platelet inhibition. Cangrelor is an intravenous antiplatelet agent which can provide almost&#xD;
      immediate strong platelet inhibition. The investigators aim to compare a strategy of&#xD;
      cangrelor administered on top of ticagrelor-an oral antiplatelet agent- vs ticagrelor alone,&#xD;
      on their efficacy to inhibit platelet function in the early hours of an acute myocardial&#xD;
      infarction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A rapid and consistent platelet inhibition represents the cornerstone of pharmacological&#xD;
      treatment in the early hours of ST-segment elevation myocardial infarction (STEMI) with&#xD;
      expected improvement in outcome. Current practice guidelines recommend administration of a&#xD;
      loading dose (LD) of an oral P2Y12 receptor antagonist as early as possible or at the time of&#xD;
      percutaneous coronary intervention (PCI) or at first medical contact.&#xD;
&#xD;
      Pharmacodynamic data have clearly shown a delay in the onset of action when prasugrel or&#xD;
      ticagrelor are administered in patients with STEMI - compared to what is obtained in stable&#xD;
      or acute coronary syndrome (ACS) patients-, which is most likely caused by an impaired&#xD;
      absorption. Peri-interventional platelet inhibition is therefore suboptimal in most cases of&#xD;
      timely performed primary PCI, even when novel oral antiplatelet agents with faster than&#xD;
      clopidogrel action are used. Modifications of the loading dose or antiplatelet pre-hospital&#xD;
      administration may only partially 'bridge the gap&quot; in platelet inhibition.&#xD;
&#xD;
      On the other hand, cangrelor is a parenteral P2Y12 antagonist, with a rapid -within minutes-&#xD;
      onset of action, able to provide very strong and consistent platelet inhibition and with&#xD;
      rapid offset of action- within 60 min of infusion discontinuation. In the CHAMPION PHOENIX&#xD;
      (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)&#xD;
      trial cangrelor reduced the incidence of ischemic events, without increasing the incidence of&#xD;
      severe bleeding. Ticagrelor is an oral antiplatelet agent which has been reported that can be&#xD;
      given before or during infusion of cangrelor without attenuation of cangrelor's&#xD;
      pharmacodynamic effects, while the pharmacodynamic effects of ticagrelor are preserved when&#xD;
      ticagrelor is given during infusion of cangrelor. It seems therefore, that ticagrelor has&#xD;
      favorable characteristics for patients intended to receive cangrelor.&#xD;
&#xD;
      In the present study, in STEMI patients undergoing primary PCI the investigators aim to&#xD;
      compare platelet inhibition achieved in patients loaded with ticagrelor followed by cangrelor&#xD;
      (bolus plus infusion) vs ticagrelor alone loaded patients.&#xD;
&#xD;
      This will be a prospective, randomized, 3-center, single-blind, investigator-initiated study&#xD;
      of parallel design to compare platelet inhibition provided by ticagrelor LD plus cangrelor&#xD;
      (bolus and infusion) vs ticagrelor LD alone. Participants will be consecutive P2Y12&#xD;
      inhibitor-naive STEMI patients with pain onset&lt;12 hours admitted for primary PCI will be&#xD;
      considered.&#xD;
&#xD;
      Participants in both arms will receive ticagrelor 180 mg LD as early as possible (e.g. in the&#xD;
      spoke hospital in case of transfer or at the emergency department in cases of hub hospital&#xD;
      presentation), as per local practice. The exact time of ticagrelor administration will be&#xD;
      recorded. Randomization followed by immediate initiation of cangrelor administration will be&#xD;
      performed after angiography and immediately prior to PCI. Patients will be randomized (Hour&#xD;
      0) in a 1:1 ratio by an independent investigator to cangrelor 30 mcg/kg bolus + 4 mcg/kg/min&#xD;
      for 2 hours, or no IV antiplatelet .&#xD;
&#xD;
      Other treatment will be as per local standard of care in all participants. Investigators who&#xD;
      will perform platelet function testing will be blind to the actual treatment assignment,&#xD;
      whereas an independent investigator will monitor bleeding and adverse event data.&#xD;
&#xD;
      Platelet reactivity will be measured at randomization (Hour 0) and at 15 min, 1, 2 and 4&#xD;
      hours post randomization. Platelet function testing will be performed with the VerifyNow&#xD;
      (Accumetrics Inc, San Diego, CA) point-of-care P2Y12 function assay within 30 min from blood&#xD;
      sample collection. Platelet reactivity results will be reported in P2Y12 reaction units (PRU)&#xD;
      and % inhibition. The % inhibition is calculated as: ([BASE-PRU]/BASE)×100. High platelet&#xD;
      reactivity (HPR) will be defined as ≥208 PRU.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 28, 2017</start_date>
  <completion_date type="Actual">December 26, 2017</completion_date>
  <primary_completion_date type="Actual">November 26, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet reactivity between the 2 arms</measure>
    <time_frame>15 min</time_frame>
    <description>Platelet reactivity in P2Y12 reaction units by VerifyNow assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity between the 2 arms</measure>
    <time_frame>1 hour</time_frame>
    <description>Platelet reactivity in P2Y12 reaction units by VerifyNow assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity between the 2 arms</measure>
    <time_frame>2 hours</time_frame>
    <description>Platelet reactivity in P2Y12 reaction units by VerifyNow assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity between the 2 arms</measure>
    <time_frame>4 hours</time_frame>
    <description>Platelet reactivity in P2Y12 reaction units by VerifyNow assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High on treatment platelet reactivity rate</measure>
    <time_frame>15 min</time_frame>
    <description>High on treatment platelet reactivity rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High on treatment platelet reactivity rate</measure>
    <time_frame>1 hour</time_frame>
    <description>High on treatment platelet reactivity rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High on treatment platelet reactivity rate</measure>
    <time_frame>2 hours</time_frame>
    <description>High on treatment platelet reactivity rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High on treatment platelet reactivity rate</measure>
    <time_frame>4 hours</time_frame>
    <description>High on treatment platelet reactivity rate</description>
  </secondary_outcome>
  <other_outcome>
    <measure>major adverse cardiac events (death, myocardial infarction, stroke, ischemia driven revascularization)</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Bleeding events (BARC classification)</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Other adverse events</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>Cangrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor will be followed by Cangrelor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ticagrelor only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 180 mg loading dose</intervention_name>
    <description>Ticagrelor 180 mg</description>
    <arm_group_label>Cangrelor</arm_group_label>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Ticagrelor 180 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min</intervention_name>
    <description>Intravenous Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min for 2 hours</description>
    <arm_group_label>Cangrelor</arm_group_label>
    <other_name>Cangrelor bolus and infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consecutive P2Y12 inhibitor-naive STEMI patients with pain onset&lt;12 hours admitted for&#xD;
             primary PCI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  a history of stroke/transient ischemic attack&#xD;
&#xD;
          -  bleeding diathesis&#xD;
&#xD;
          -  chronic oral anticoagulation treatment&#xD;
&#xD;
          -  contraindications to anti platelet therapy&#xD;
&#xD;
          -  PCI or coronary artery bypass grafting &lt;3 months&#xD;
&#xD;
          -  platelet count &lt;100 000/μL&#xD;
&#xD;
          -  hematocrit &lt;30%&#xD;
&#xD;
          -  creatinine clearance &lt;30 mL/min&#xD;
&#xD;
          -  severe hepatic dysfunction&#xD;
&#xD;
          -  use of strong CYP3A inhibitors or inducers&#xD;
&#xD;
          -  increased risk of bradycardia&#xD;
&#xD;
          -  severe chronic obstructive pulmonary disease&#xD;
&#xD;
          -  periprocedural IIb/IIIa inhibitor administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitrios Alexopoulos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Attikon Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Attikon University Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attika</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>December 26, 2017</last_update_submitted>
  <last_update_submitted_qc>December 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Attikon Hospital</investigator_affiliation>
    <investigator_full_name>Dimitrios Alexopoulos</investigator_full_name>
    <investigator_title>Professor of Cardiology, National and Capodestrian University of Athens</investigator_title>
  </responsible_party>
  <keyword>cangrelor</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>P2Y12 receptor antagonist</keyword>
  <keyword>acute myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Cangrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

